Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brian Yang

Beijing-based Brian Yang is a senior writer in charge of overall China coverage within the APAC Pharma news team. A veteran journalist, he has written extensively on pharmaceutical R&D, regulatory affairs and market access for PharmAsia News. Brian’s intimate industry knowledge and in-depth analysis has won wide praise and helped secure exclusive interviews with top biopharma executives.
He has led a team of writers to provide industry-leading coverage on key issues such as multi-regional clinical trials, priority reviews and go-to-market strategies in a highly-dynamic and fast-changing market, with the on-the-ground coverage consistently ranked among the top-read in PharmAsia News.

Prior to joining Informa, Brian worked as a foreign affairs correspondent for two TV networks and web editor for an international radio station. Trilingual in Mandarin Chinese, English and Japanese, he obtained his BA degree from China and an MA degree from Japan.

Advertisement
Set Alert for Articles By Brian Yang

Latest From Brian Yang

What’s At Stake As China Expands '4+7' Scheme: An Infographic Snapshot

China’s massive centralized "4+7" drug procurement scheme is now being rolled out nationwide, involving some of the largest provincial markets and huge product volumes.

China Policy & Regulation

Regulatory Digital Savvy: Taking China NMPA's New App For A Test Drive

At just the time when pretty much everything is going digital in China, the nation’s pharma regulatory agency has launched a new mobile application to put itself at your finger tips. And it’s time to give it a test drive.

China Regulation

China Widens MAH Scheme To Medtech As Consumables Face Price Cuts

China is quickly expanding its marketing authorization holder scheme from drugs to devices. It is also vowing to reduce medical costs by using more low-cost, domestic consumables, which will have a significant impact on companies.

Regulation Medical Device

BeiGene Rebuts Short-Seller Allegations, But Real Challenges May Lie Elsewhere

A report from a short-seller firm has put Beijing-based biotech bellwether BeiGene in an unwanted spotlight, prompting management to defend its record.

China Business Strategies

China's New Pharma Law Leaves Key Questions Unanswered

Much anticipated legislation signals flexibility over online sales of pharma products and definition of counterfeits, but the law also falls short on key elements of pharmaceutical innovation and intellectual property rights protection, says one legal expert.

Legislation Regulation

Breaking Away From Betta, Jacobio Raises China Oncology Development Bar

Emerging Company Profile: Founded by former executives of China’s national innovation darling Betta Pharma, Beijing-based Jacobio is focused on novel oncology assets, led by a KRAS inhibitor that's set to begin Phase I and IIa studies in the US and China for solid tumors.

StartUps and SMEs Cancer
See All
Advertisement
UsernamePublicRestriction

Register